Dr. D'Adamo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1997 - 1999
New York University School of MedicineClass of 1997
Certifications & Licensure
NY State Medical License 1998 - 2022
MA State Medical License 2011 - 2014
Clinical Trials
- Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery Start of enrollment: 2004 Oct 01
Publications & Presentations
PubMed
- 235 citationsMulticenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor SarcomasSuzanne George, Priscilla Merriam, Robert G. Maki, Annick D. Van den Abbeele, Jeffrey T. Yap
Journal of Clinical Oncology. 2009-07-01 - 409 citationsPhase II Study of Sorafenib in Patients With Metastatic or Recurrent SarcomasRobert G. Maki, David R. D'Adamo, Mary L. Keohan, Michael Saulle, Scott M. Schuetze
Journal of Clinical Oncology. 2009-07-01 - 595 citationsCrizotinib in ALK-rearranged inflammatory myofibroblastic tumor.James E. Butrynski, David R. D'Adamo, Jason L. Hornick, Paola Dal Cin, Cristina R. Antonescu
The New England Journal of Medicine. 2010-10-28
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
